Table 1.
Changes in total and free antiretroviral concentration during third trimester of pregnancy compared to postpartum with the corresponding fraction unbound
| Mean ratio Ctot (%) TT/PP | Mean ratio Cfree (%) TT/PP | Fu (%) | Ref | ||
|---|---|---|---|---|---|
| TT | PP | ||||
| Rilpivirine (n = 11) | 10 | ||||
| C min | 58 | 64 | 0.28b | 0.23b | |
| C max | 80 | 90 | |||
| Darunavir (twice daily; n = 5) | 11 | ||||
| C 12 | 89 | 105a | 12 | 10 | |
| C max | 76 | 92a | |||
| Darunavir (once daily; n = 8) | |||||
| C 24 | 59 | 67a | |||
| C max | 78 | 94a | |||
| Darunavir (once daily; n = 12) | 12 | ||||
| C min | 50 | 62 | 23 | 18 | |
| C max | 69 | 84 | |||
| Etravirine (n = 10) | 13 | ||||
| C min | 111 | 92 | 0.075 | 0.083 | |
| C max | 135 | 107 | |||
| Lopinavir (n = 30) | 14 | ||||
| C min | 69 | 79 | 0.84 | 0.68 | |
TT, third trimester; PP, postpartum; n, represents the number of paired observations
a
Inferred from the reported fraction unbound during third trimester of pregnancy and postpartum.
b
Inferred from reported secondary total and free PK parameters (Cmax).